2cureX has signed a distribution agreement with specialized diagnostic solutions leader Werfen, to distribute 2cureX products in SpainADAPT
- Development of an automated system for handling and deposition of tumoroids.
- ADAPT is a joint project conducted in collaboration with engineers at the Hahn-Schickard Institute for Microanalysis Systems and the Department of Microsystems Engineering (IMTEK) at the University of Freiburg. The project is financed by a 1.000.000 EUR grant from the “Alternative Methods to Animal Testing” initiative of the German Federal Ministry of Education and Research. 2cureX will receive 110.500 EUR to validate the novel technology and integrate it into the IndiTreat® test.
- The funds enable the development of a device for in vitro experiments with tumoroids from human tissue that meets the requirements for personalized medicine in terms of miniaturization, standardization, automation, flexibility and throughput.
- Automation of tumoroid handling will increase the applicability of functional testing in clinical practice and improve the precision of the IndiTreat® test. This will ensure constant operator-independent quality standards across different hospitals where IndiTreat® is being implemented.
- ADAPT started in April 2020 and will run for 36 month.
![](https://www.2curex.com/wp-content/uploads/federal-minstry.jpg")
![](https://www.2curex.com/wp-content/uploads/hahn-schickard.jpg")
![](https://www.2curex.com/wp-content/uploads/imtek.jpg")
Project Details
Acronym:
ADAPT
Grant agreement ID:
031L0235C
Duration:
36 months
Start date:
1 April 2020
Topic:
Alternative Methods to Animal Testing
Funding:
110.500 EUR
Upcoming events
December 7, 2021
CEO Fernando Andreu will present at ”Sedermeradagen Köbenhamn 2021” (Copenhagen, Denmark)
December 9, 2021
2cureX presents at HC Andersen Capital’s Virtual Growth Days (Copenhagen, Denmark)
January 20, 2022
2cureX present at Redeye Theme – Fight Cancer Seminar – Outlook 2022 (Stockholm, Sweden)